SCHEMBL17685693

SCHEMBL17685693

COc1cccc(-c2nc3ccccc3[nH]2)c1OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 3/20 0.60
PDE5A O76074 5/20 0.51
PDE4A P27815 2/20 0.51
PDE4B Q07343 2/20 0.51
PDE4C Q08493 2/20 0.51
PDE4D Q08499 2/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
SLC2A1 P11166 1/20 0.47
ALDH1A1 P00352 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
AURKA O14965 1/20 0.46
EGFR P00533 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30835050 0.83 PDE5A (0.70) AMY1APDE5APDE4APDE4BPDE4C
SCHEMBL28286332 0.83 PDE5A (0.70) AMY1APDE5APDE4APDE4BPDE4C
SCHEMBL10745905 0.80 AMY1A (0.53) AMY1APDE5APDE4APDE4BPDE4C
SCHEMBL31027930 0.79 AMY1A (0.76) AMY1APDE5ANPC1RAB9ASMN1; SMN2
SCHEMBL2096956 0.79 AMY1A (0.76) AMY1APDE5ANPC1RAB9ASMN1; SMN2
SCHEMBL12242149 0.77 ABL1 (0.50) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL9009626 0.77 AMY1A (0.67) AMY1APDE5ANPC1RAB9ASMN1; SMN2
SCHEMBL6520239 0.76 PDE4A (0.67) AMY1APDE4APDE4BPDE4CPDE4D
SCHEMBL25885094 0.76 AMY1A (0.46) AMY1APDE5APDE4APDE4BPDE4C
SCHEMBL7393458 0.76 AMY1A (0.71) AMY1APDE5ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255853-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2025-08-14 US disclosed
US-20240285592-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2024-08-29 US disclosed
US-11951099-B2 Methods for treating plasma cell neoplasm with human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2024-04-09 US disclosed
CN-107106519-B Therapeutic agent for human 安克生命科学公司 2023-01-24 CN disclosed
CN-115569136-A Therapeutic agent for human 安克生命科学公司 2023-01-06 CN disclosed
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2022-05-19 US disclosed
US-11266634-B2 Methods for treating melanoma with human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2022-03-08 US disclosed
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2020-12-10 US disclosed
US-10751330-B2 Human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2020-08-25 US disclosed
US-10744124-B2 Human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2020-08-18 US disclosed
US-20170105976-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF Ions Pharmaceutical S.à r.I. (LU) 2017-04-20 US disclosed
US-20170105975-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-04-20 US disclosed
US-20170042867-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-02-16 US disclosed
US-20170042865-A1 THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-02-16 US disclosed
US-20170042866-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-02-16 US disclosed
US-9402834-B2 Human therapeutic agents IONS PHARMACEUTICAL S.À R.L. (LU) 2016-08-02 US disclosed
US-20160106687-A1 HUMAN THERAPEUTIC AGENTS IONS PHARMACEUTICAL S.À R.L. (LU) 2016-04-21 US disclosed
US-20160106722-A1 HUMAN THERAPEUTIC AGENTS IONS PHARMACEUTICAL S.À R.L. (LU) 2016-04-21 US disclosed
US-20160106721-A1 HUMAN THERAPEUTIC AGENTS IONS PHARMACEUTICAL S.À R.L. (LU) 2016-04-21 US disclosed
US-20160106724-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2016-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10744124-B2 Human therapeutic agents INMT, HNMT, HASPIN AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885
US-11266634-B2 Methods for treating melanoma with human therapeutic agents HNMT, INMT, TYR AMY1A 4678/4885PDE5A 4228/4885PDE4A 2389/4885
US-11951099-B2 Methods for treating plasma cell neoplasm with human therapeutic agents MCL1, CD44, INMT AMY1A 4364/4885PDE5A 4668/4885PDE4A 4359/4885
US-10751330-B2 Human therapeutic agents INMT, HNMT, HASPIN AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885
US-20240285592-A1 HUMAN THERAPEUTIC AGENTS INMT, NLN, MYC AMY1A 4763/4885PDE5A 4733/4885PDE4A 4292/4885
US-20170042865-A1 THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, CPT1A AMY1A 4414/4885PDE5A 4179/4885PDE4A 3339/4885
US-20170105976-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT AMY1A 4652/4885PDE5A 3896/4885PDE4A 2781/4885
US-20170042867-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT AMY1A 4652/4885PDE5A 3896/4885PDE4A 2781/4885
US-20170042866-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT AMY1A 4652/4885PDE5A 3896/4885PDE4A 2781/4885
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885
US-20160106722-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885
US-20170105975-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT AMY1A 4652/4885PDE5A 3896/4885PDE4A 2781/4885
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885
US-20160106721-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885
US-20250255853-A1 HUMAN THERAPEUTIC AGENTS HASPIN, TIPARP, SHARPIN AMY1A 2904/4885PDE5A 4669/4885PDE4A 3687/4885
US-20160106724-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885
US-20160106687-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN AMY1A 4474/4885PDE5A 4757/4885PDE4A 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.